Holdings
PSP Research LLC
As of Jun 30, 2026, PSP Research LLC reported 63 positions worth US$23.4M. Largest: Nurix Therapeutics, Inc., Incyte Corporation and Argenx Se. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Nurix Therapeutics, Inc. | 25,000 | US$607K | −3,700 | Jun 30, 2026 |
| Incyte Corporation | 5,300 | US$601K | no change | Jun 30, 2026 |
| Argenx Se | 641 | US$595K | no change | Jun 30, 2026 |
| Disc Medicine, Inc. | 8,000 | US$585K | no change | Jun 30, 2026 |
| Rapport Therapeutics, Inc. | 14,000 | US$583K | no change | Jun 30, 2026 |
| Ultragenyx Pharmaceutical Inc. | 17,000 | US$568K | −5,100 | Jun 30, 2026 |
| Trevi Therapeutics, Inc. | 30,000 | US$560K | no change | Jun 30, 2026 |
| Monte Rosa Therapeutics, Inc. | 23,000 | US$557K | −5,000 | Jun 30, 2026 |
| Tg Therapeutics, Inc. | 10,000 | US$549K | −3,000 | Jun 30, 2026 |
| Halozyme Therapeutics, Inc. | 7,000 | US$548K | −1,026 | Jun 30, 2026 |